Evidence map›Paper›PMID 29707144›Full record

ArticleOncotarget2018

Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer.

Agnieszka Dansonka-Mieszkowska, Lukasz M Szafron, Joanna Moes-Sosnowska, Mariusz Kulinczak, Anna Balcerak, Bozena Konopka, Magdalena Kulesza, Agnieszka Budzilowska, Martyna Lukasik, Urszula Piekarska and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Genetic Ancestry Analysis Reveals Misclassification of Commonly Used Cancer Cell Lines.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Agnieszka Dansonka-MieszkowskaDepartment of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Lukasz M SzafronDepartment of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Joanna Moes-SosnowskaDepartment of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Mariusz KulinczakDepartment of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Anna BalcerakDepartment of Molecular and Translational Oncology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Bozena KonopkaDepartment of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Magdalena KuleszaDepartment of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Agnieszka BudzilowskaDepartment of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Martyna LukasikDepartment of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Urszula PiekarskaDepartment of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Iwona K RzepeckaDepartment of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Joanna ParadaDepartment of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Renata ZubDepartment of Molecular and Translational Oncology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Barbara Pienkowska-GrelaCytogenetics Laboratory, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Radoslaw MadryDepartment of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Jan K SiwickiDepartment of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Jolanta KupryjanczykDepartment of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
The Maria Sklodowska-Curie National Research Institute of Oncology · PLPoznan University of Medical Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EMSY, a BRCA2-associated protein, is amplified and overexpressed in various sporadic cancers. This is the first study assessing the clinical impact of its expression and polymorphisms on ovarian cancer (OvCa) outcome in the context of the chemotherapy regimen used. In 134 frozen OvCa samples, we assessed

Indexed as

chemotherapyEMSYgene expressionovarian cancerpolymorphism

Identifiers

PMID29707144
PMCPMC5915152
OpenAlexW2795920785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.